Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
May have a role in the regulation of spermatogenesis.. De plus, nous expédions PD-1 Protéines (102) et PD-1 Kits (27) et beaucoup plus de produits pour cette protéine.
Showing 10 out of 744 products:
Human Polyclonal PD-1 Primary Antibody pour BR, CyTOF - ABIN5012979
Wan, Nie, Liu, Feng, He, Xu, Zhang, Dong, Zhang: Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. dans Journal of immunology (Baltimore, Md. : 1950) 2007
Show all 11 Pubmed References
Human Polyclonal PD-1 Primary Antibody pour ELISA (Detection), FACS - ABIN4899871
Sakthivel, Ramanujam, Wang, Pirskanen, Lefvert: Programmed Death-1: from gene to protein in autoimmune human myasthenia gravis. dans Journal of neuroimmunology 2008
Show all 9 Pubmed References
Human Monoclonal PD-1 Primary Antibody pour BR, FACS - ABIN2689142
Bennett, Luxenberg, Ling, Wang, Marquette, Lowe, Khan, Veldman, Jacobs, Valge-Archer, Collins, Carreno: Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. dans Journal of immunology (Baltimore, Md. : 1950) 2003
Show all 8 Pubmed References
Mouse (Murine) Monoclonal PD-1 Primary Antibody pour BR, FACS - ABIN2689141
Nishimura, Agata, Kawasaki, Sato, Imamura, Minato, Yagita, Nakano, Honjo: Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. dans International immunology 1997
Show all 7 Pubmed References
Human Polyclonal PD-1 Primary Antibody pour IHC, ELISA - ABIN1002980
Holling, Schooten, van Den Elsen: Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. dans Human immunology 2004
Show all 4 Pubmed References
Human Polyclonal PD-1 Primary Antibody pour IHC, ELISA - ABIN1002981
Ishida, Agata, Shibahara, Honjo: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. dans The EMBO journal 1992
Show all 4 Pubmed References
Human Monoclonal PD-1 Primary Antibody pour ICC, FACS - ABIN438813
Dorrell, Abraham, Lanxon-Cookson, Canaday, Streeter, Grompe: Isolation of major pancreatic cell types and long-term culture-initiating cells using novel human surface markers. dans Stem cell research 2009
Show all 3 Pubmed References
Mouse (Murine) Polyclonal PD-1 Primary Antibody pour CyTOF, FACS - ABIN4899873
Kasagi, Kawano, Okazaki, Honjo, Morinobu, Hatachi, Shimatani, Tanaka, Minato, Kumagai: Anti-programmed cell death 1 antibody reduces CD4+PD-1+ T cells and relieves the lupus-like nephritis of NZB/W F1 mice. dans Journal of immunology (Baltimore, Md. : 1950) 2010
Show all 3 Pubmed References
Human Polyclonal PD-1 Primary Antibody pour IF (p), IHC (p) - ABIN735608
Zhang, Niyazi, Hong, Tuluwengjiang, Zhang, Zhang, Su, Bao: Effect of EBI3 on radiation-induced immunosuppression of cervical cancer HeLa cells by regulating Treg cells through PD-1/PD-L1 pathway. dans Tumour biology 2017
Show all 2 Pubmed References
Human Monoclonal PD-1 Primary Antibody pour FACS - ABIN2479653
Ochonisky, Chosidow, Kuentz, Man, Fraitag, Pelisse, Revuz: Cogan's syndrome. An unusual etiology of urticarial vasculitis. dans Dermatologica 1992
Show all 3 Pubmed References
The G allele of rs36084323 of PDCD1 is associated with increased risk of advanced TNM (Montrer ODZ1 Anticorps) staging of colorectal cancer.
promoter methylation of CTLA4, PD-L1, PD-L2, and PD-1 in diffuse lower-grade gliomas (LGG) harboring isocitrate dehydrogenase (IDH) mutation, is reported.
Unlike other multiple autoimmune disease associated genetic variants, there was no association between PDCD1 variants and Juvenile Idiopathic Arthritis
Alteration of the PD-1/PD-L1 (Montrer CD274 Anticorps) pathway can modulate Treg/Th17 balance in asthmatic children.
The expression of PD1 on T cells was elevated in patients with rheumatoid arthritis and was correlated with the disease activity.
High expression of programmed death-1 in sentinel lymph nodes is associated with breast cancer.
We describe three cases of patients with mRCC treated with anti-PD-1 antibody therapy in combination with targeted therapy (bevacizumab), anti-cytotoxic T lymphocyte antigen 4 (Montrer CTLA4 Anticorps) therapy (ipilimumab), or radiotherapy.
anti-CTLA4 (Montrer CTLA4 Anticorps)/anti-PD-1/PD-L1 (Montrer CD274 Anticorps) combinations versus anti-PD-1/PD-L1 (Montrer CD274 Anticorps) monotherapy was selected as a factor independent of TMB (Montrer MRPL55 Anticorps) for predicting better RR (77% vs. 21%; P = 0.004) and PFS (P = 0.024). Higher TMB (Montrer MRPL55 Anticorps) predicts favorable outcome to PD-1/PD-L1 (Montrer CD274 Anticorps) blockade across diverse tumors.
The altered soluble (s)PD1 and sICOS serum levels in the different Hepatitis b (HBV) groups may reflect the dysregulation of T cell activation, and may be associated with the HBV pathological process.
We found that PD-L1 (Montrer CD274 Anticorps) expression was upregulated following TGF-beta (Montrer TGFB1 Anticorps) induction; in contrast, it was downregulated by TGF-beta (Montrer TGFB1 Anticorps) receptor-kinase inhibitors and the MET process. Furthermore, chemo-treatment increased TGF-beta (Montrer TGFB1 Anticorps) expression and enhances PD-L1 (Montrer CD274 Anticorps) expression via autocrine TGF-beta (Montrer TGFB1 Anticorps) induced EMT (Montrer ITK Anticorps). Analysis of clinical samples revealed a significant relationship between PD-L1 (Montrer CD274 Anticorps) expression and EMT (Montrer ITK Anticorps) status
These results show that PD-1 plays an inhibitory role during the naive-to-effector CD8 (Montrer CD8A Anticorps) T cell transition and that the PD-1 pathway can also be modulated at this stage of T cell differentiation.
Blockade of CCR5-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy in gastric cancer
T-cell activation mediates the immunopreventive effects of anti-PD-1; PD-1 on T cells interacts with the PD-1 ligand PD-L1 (Montrer CD274 Anticorps) on cancer cells
these data show that PD-1 expression is an intrinsic property of brain-resident memory CD8 (Montrer CD8A Anticorps) T cells in a persistent CNS viral infection
Our results demonstrate that entinostat enhances the antitumor effect of PD-1 targeting through functional inhibition of MDSCs and a transition away from an immune-suppressive tumor microenvironment. These data provide a mechanistic rationale for the clinical testing and potential markers of response of this novel combination in solid tumor patients.
synergism in cell death by Caspase-1 (Montrer CASP1 Anticorps)- and RipK3 (Montrer RIPK3 Anticorps) resulted in restriction of PD-1 and TIM3 (Montrer HAVCR2 Anticorps) expression on primed CD8 (Montrer CD8A Anticorps)(+) T cells, which promoted the survival of activated CD8 (Montrer CD8A Anticorps)(+) T cells.
Tim-3 (Montrer HAVCR2 Anticorps) and PD-1 pathways play critical roles in regulating CD8 (Montrer CD8A Anticorps)(+) T cell function and maintaining normal pregnancy.
Anti-PD-1/PD-L1 (Montrer CD274 Anticorps) therapy inhibited CMT167 orthotopic lung tumors by 95%. .Silencing PD-L1 (Montrer CD274 Anticorps) expression in CMT167 cells resulted in smaller orthotopic tumors that remained sensitive to anti-PD-L1 (Montrer CD274 Anticorps) therapy, whereas implantation of CMT167 cells into PD-L1 (Montrer CD274 Anticorps)(-) mice blocked orthotopic tumor growth, indicating a role for PD-L1 (Montrer CD274 Anticorps) in both the cancer cell and the microenvironment.
Combination therapies that depend on checkpoint inhibitor antibodies (Abs) such as for PD-1 or its ligand (PD-L1 (Montrer CD274 Anticorps)) together with immune stimulatory agonist Abs like anti-OX40 (Montrer TNFRSF4 Anticorps) are being tested in the clinic to achieve improved antitumor effects
Inhibition of Fut8 (Montrer FUT8 Anticorps), a core fucosyltransferase, by genetic ablation or pharmacologic inhibition reduced cell-surface expression of PD-1 and enhanced T cell activation, leading to more efficient tumor eradication.
Data show that CTLA-4 (Montrer CTLA4 Anticorps)(+)PD-1(-) memory CD4 (Montrer CD4 Anticorps)(+) T cells, which share phenotypic markers with regulatory T cells, were enriched in SIV DNA in blood, lymph nodes (LN), spleen, and gut (Montrer GUSB Anticorps), and contained replication-competent and infectious virus.
Compared to before immunosuppression, PD-1 expression increased at reactivation. Increased T cells before zoster is likely due to virus reactivation.
A PD-1(high) phenotype is associated with accelerated in vivo CD8 (Montrer CD8A Anticorps) T cell turnover in SIV-infections, especially within the SIV-specific CD8 (Montrer CD8A Anticorps) T cell pool.
High levels of PD-1 expression on CD4 (Montrer CD4 Anticorps)(+) T cells in lymph nodes of rhesus macaques can serve as a valuable marker to identify T follicular helper cells.
Data indicate that PD-1 expression is increased as a result of T cell activation during a primary immune response as well as during persistent immune activation in macaques.
PD-1 can serve as a sensitive indicator of persistent, low-level virus replication
This gene encodes a cell surface membrane protein of the immunoglobulin superfamily. This protein is expressed in pro-B-cells and is thought to play a role in their differentiation. In mice, expression of this gene is induced in the thymus when anti-CD3 antibodies are injected and large numbers of thymocytes undergo apoptosis. Mice deficient for this gene bred on a BALB/c background developed dilated cardiomyopathy and died from congestive heart failure. These studies suggest that this gene product may also be important in T cell function and contribute to the prevention of autoimmune diseases.
programmed cell death protein 1
, protein PD-1
, programmed cell death 1
, programmed death 1